drugset / Trial / NCT05932173
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
Phase 1/2
Unknown
60 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NaSingle-groupOpen-labelTreatment
Summary
It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+ refractory/relapsed B-Cell malignancies.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OlyCAR-019 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | OlyCAR-019 | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | OlyCAR-019 | Cell therapy | 5e+06 cells/kg | Intravenous |